Programs

Closed

This organization closed in 2024. It filed a final 990 indicating termination and no longer appears as active in IRS records, as it is absent from the EO Business Master File and Pub78 List.

  • Program 1 [2019]

    THE ROSS K. MACNEILL FOUNDATION'S (R33M) MISSION IS TO END PEDIATRIC BRAIN CANCER. OUR METHOD TO THAT END IS TO RAISE AWARENESS FOR THE DIAGNOSIS OF PEDIATRIC BRAIN CANCER TO INSPIRE DONATIONS THAT CAN SUPPORT RESEARCH. WE FUND RESEARCH FOR INNOVATIVE, NON-TOXIC THERAPIES TO TREAT A CHILD'S TUMOR SO THAT THEY CAN CONTINUE TO LEAD HEALTHY, FULL AND PRODUCTIVE LIVES. TODAY A CHILD WITH A BRAIN TUMOR WILL LIKELY NOT SURVIVE TO SEE MIDDLE SCHOOL. 50% OF CHILDREN WITH A BRAIN TUMOR DO NOT SURVIVE. OUR DEDICATION TO FUNDING RESEARCH IS BECAUSE CURRENTLY, AND FOR DECADES, THE NIH HAS FUNDED PEDIATRIC CANCER RESEARCH WITH <4% OF THEIR BUDGET. FUNDING RECEIVED FOR PEDIATRIC BRAIN CANCER RESEARCH IS <1% OF THAT 4%. THIS HAS NEVER BEEN NOR WILL EVER BE ENOUGH TO FUND THE CRITICAL RESEARCH NEEDED. (SEE SCH O) ADDITIONALLY, IN THE RECENT 20+ YEARS, THERE HAS NEVER BEEN A DRUG DEVELOPED FOR CHILDREN WITH BRAIN CANCER. THE TREATMENT CHILDREN, INCLUDING ROSS, RECEIVE IS DEVELOPED FOR ADULTS AND FOR DIAGNOSES OTHER THAN BRAIN CANCER. TO UNDERSTAND THIS PRECISELY, A CHILD WITH BRAIN CANCER IS GIVEN TREATMENTS NOT MADE FOR CHILDREN AND NOT MADE FOR BRAIN CANCER. R33M'S DEVOTION TO FUNDING RESEARCH IS CRITICAL TO SAVING LIVES OF CHILDREN. WE WORK FULL-TIME TO ESTABLISH RELATIONSHIPS WITH THE LEADING INSTITUTIONS WORLD-WIDE ALONG WITH THE LEADING SCIENTISTS IN THIS WORK TO ASSURE THAT OUR INVESTMENTS ARE WITH THE MOST PROMISING, INNOVATIVE WORK. TREMENDOUS PROGRESS HAS BEEN MADE ON BEHALF OF CHILDREN AND THE MISSION OF R33M IS OBTAINABLE. WE ARE PRIVILEGED TO DO THIS WORK.
    Geographies
    Not indicated
    Dates
    Jan 1, 2019 – Dec 31, 2019
    Source
    990
    No causes provided
    No populations provided
    –
    $214.7K

  • Program 1 [2020]

    THE ROSS K. MACNEILL FOUNDATION'S (R33M) MISSION IS TO END PEDIATRIC BRAIN CANCER. OUR METHOD TO THAT END IS TO RAISE AWARENESS FOR THE DIAGNOSIS OF PEDIATRIC BRAIN CANCER TO INSPIRE DONATIONS THAT CAN SUPPORT RESEARCH. WE FUND RESEARCH FOR INNOVATIVE, NON-TOXIC THERAPIES TO TREAT A CHILD'S TUMOR SO THAT THEY CAN CONTINUE TO LEAD HEALTHY, FULL AND PRODUCTIVE LIVES. TODAY A CHILD WITH A BRAIN TUMOR WILL LIKELY NOT SURVIVE TO SEE MIDDLE SCHOOL. 50% OF CHILDREN WITH A BRAIN TUMOR DO NOT SURVIVE. OUR DEDICATION TO FUNDING RESEARCH IS BECAUSE CURRENTLY, AND FOR DECADES, THE NIH HAS FUNDED PEDIATRIC CANCER RESEARCH WITH <4% OF THEIR BUDGET. FUNDING RECEIVED FOR PEDIATRIC BRAIN CANCER RESEARCH IS <1% OF THAT 4%. THIS HAS NEVER BEEN NOR WILL EVER BE ENOUGH TO FUND THE CRITICAL RESEARCH NEEDED. ADDITIONALLY, IN THE RECENT 20+ YEARS, THERE HAS NEVER BEEN A DRUG DEVELOPED FOR CHILDREN WITH BRAIN CANCER. THE TREATMENT CHILDREN, INCLUDING ROSS, RECEIVE IS DEVELOPED FOR ADULTS AND FOR DIAGNOSES OTHER THAN BRAIN CANCER. TO UNDERSTAND THIS PRECISELY, A CHILD WITH BRAIN CANCER IS GIVEN TREATMENTS NOT MADE FOR CHILDREN AND NOT MADE FOR BRAIN CANCER. R33M'S DEVOTION TO FUNDING RESEARCH IS CRITICAL TO SAVING LIVES OF CHILDREN. WE WORK FULL-TIME TO ESTABLISH RELATIONSHIPS WITH THE LEADING INSTITUTIONS WORLD-WIDE ALONG WITH THE LEADING SCIENTISTS IN THIS WORK TO ASSURE THAT OUR INVESTMENTS ARE WITH THE MOST PROMISING, INNOVATIVE WORK. TREMENDOUS PROGRESS HAS BEEN MADE ON BEHALF OF CHILDREN AND THE MISSION OF R33M IS OBTAINABLE. WE ARE PRIVILEGED TO DO THIS WORK.
    Geographies
    Not indicated
    Dates
    Jan 1, 2020 – Dec 31, 2020
    Source
    990
    No causes provided
    No populations provided
    –
    $317.8K

  • Pediatric Brain Cancer Research Initiative

    THE ROSS K. MACNEILL FOUNDATIONS R33M MISSION IS TO END PEDIATRIC BRAIN CANCER. OUR METHOD TO THAT END IS TO RAISE AWARENESS FOR THE DIAGNOSIS OF PEDIATRIC BRAIN CANCER TO INSPIRE DONATIONS THAT CAN SUPPORT RESEARCH. WE FUND RESEARCH FOR INNOVATIVE NON-TOXIC THERAPIES TO TREAT A CHILDS TUMOR SO THAT THEY CAN CONTINUE TO LEAD HEALTHY FULL AND PRODUCTIVE LIIVES. TODAY A CHILD WITH A BRAIN TUMOR WILL LIKELY NOT SURVIVE TO SEE MIDDLE SCHOOL. 50% OF CHILDREN WITH A BRAIN TUMOR DO NOT SURVIVE. OUR DEDICATION TO FUNDING RESEARCH IS BECAUSE CURRENTLY AND FOR DECADES THE NIH HAS FUNDED PEDIATRIC CANCER RESEARCH WITH 4% OF THEIR BUDGET. FUNDING RECEIVED FOR PEDIATRIC BRAIN CANCER RESEARCH IS 1% OF THAT 4%. THIS HAS NEVER BEEN NOR WILL EVER BE ENOUGH TO FUND THE CRITICAL RESEARCH NEEDED. ADDITIONALLY IN THE RECENT 20+ YEARS THERE HAS NEVER BEEN A DRUG DEVELOPED FOR CHILDREN WITH BRAIN CANCER. THE TREATMENT CHILDREN INCLUDING ROSS RECEIVE IS DEVELOPED FOR ADULTS AND FOR DIAGNOSES OTHER THAN BRAIN CANCER. TO UNDERSTAND THIS PRECISELY A CHILD WITH BRAIN CANCER IS GIVEN TREATMENTS NOT MADE FOR CHILDREN AND NOT MADE FOR BRAIN CANCER. R33MS DEVOTION TO FUNDING RESEARCH IS CRITICAL TO SAVING LIVES OF CHILDREN. WE WORK FULL-TIME TO ESTABLISH RELATIONSHIPS WITH THE LEADING INSTITUTIONS WORK-WIDE ALONG WITH THE LEADING SCIENTISTS IN THIS WORK TO ASSURE THAT OUR INVESTMENTS ARE WITH THE MOST PROMISING INNOVATIVE OWRK. TREMENDOUS PROGRESS HAS BEEN MADE ON BEHALF OF CHILDREN AND THE MISSION OF R33M IS OBTAINABLE. WE ARE PRIVILEGED TO DO THIS WORK.
    Geographies
    Not indicated
    Dates
    Jan 1, 2024 – Dec 31, 2024
    Source
    990
    No causes provided
    No populations provided
    –
    $324.3K